141 lines
44 KiB
Text
141 lines
44 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK548834">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK548834/?report=reader">
|
|
<meta name="ncbi_pagename" content="Lorcaserin - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Lorcaserin - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Lorazepam/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/Lorlatinib/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Lorcaserin">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2020/06/05">
|
|
<meta name="citation_pmid" content="31644141">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548834/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Lorcaserin">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2020/06/05">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548834/">
|
|
<meta name="description" content="Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight years when it was withdrawn because of concerns regarding an excess in cancer risk after long term use. In prelicensure studies and while in clinical use, lorcaserin was not found to be associated with serum enzyme elevations during therapy or to instances of clinically apparent liver injury.">
|
|
<meta name="og:title" content="Lorcaserin">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight years when it was withdrawn because of concerns regarding an excess in cancer risk after long term use. In prelicensure studies and while in clinical use, lorcaserin was not found to be associated with serum enzyme elevations during therapy or to instances of clinically apparent liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548834/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Lorcaserin/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548834/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DDDA07D7D72910000000000B60092.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK548834/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Lorazepam/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Lorcaserin</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/Lorlatinib/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK548834/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK548834/&text=Lorcaserin"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK548834/?report=classic">Switch to classic view</a><a href="/books/NBK548834/pdf/Bookshelf_NBK548834.pdf">PDF (101K)</a><a href="/books/NBK548834/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK548834%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DDDA07D7D72910000000000B60092.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK548834_"><span class="title" itemprop="name">Lorcaserin</span></h1><p class="fm-aai"><a href="#_NBK548834_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Lorcaserin.OVERVIEW"><h2 id="_Lorcaserin_OVERVIEW_">OVERVIEW</h2><div id="Lorcaserin.Introduction"><h3>Introduction</h3><p>Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight years when it was withdrawn because of concerns regarding an excess in cancer risk after long term use. In prelicensure studies and while in clinical use, lorcaserin was not found to be associated with serum enzyme elevations during therapy or to instances of clinically apparent liver injury.</p></div><div id="Lorcaserin.Background"><h3>Background</h3><p>Lorcaserin (lor ka' ser in) is a serotonin agonist that is relatively selective for the serotonin 2C (5-HT2C) receptor, that is located almost exclusively in the brain. Activation of this receptor activates pathways important in hunger and satiety, including those that induce proopiomelanocortin which decreases appetite. In several premarketing controlled trials, lorcaserin was found to lead to greater weight loss than placebo. Lorcaserin was officially approved for use in the United States in 2012, but was recommended only for patients who were obese (BMI ≥30) or who were overweight (BMI ≥27-30) and had a significant obesity related condition. In early 2020, lorcaserin was withdrawn from clinical use because of long term studies suggesting an increased risk of cancer with its use. Lorcaserin was available in 10 mg tablets under the commercial name Belviq. The recommended dose was 10 mg twice daily. An extended release formulation, available as 20 mg tablets (Belviq XR), was developed which allowed for once daily administration. Commonly reported side effects were headache, dry mouth, nausea, fatigue and dizziness which occasionally required discontinuation or dose adjustment. Severe side effects were rare and possibly included depression, serotonin syndrome and cardiac valvulopathy, although these side effects were not appreciably increased among lorcaserin treated patients in prelicensure clinical trials nor were they identified in subsequent postmarketing studies. A recent reanalysis of a large, long term trial of lorcaserin identified an excess incidence of cancer with treatment, including pancreatic, colorectal and lung cancer.</p></div><div id="Lorcaserin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In premarketing clinical trials, serum aminotransferase elevations were no more common among patients receiving lorcaserin than placebo. Clinically apparent liver injury due to lorcaserin has not been reported, but the numbers of patients treated has been limited.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Lorcaserin.Outcome_and_Management"><h3>Outcome and Management</h3><p>No instances of acute liver failure or chronic liver injury have been linked to lorcaserin, but it has had limited general clinical use and now has been withdrawn because of an increased risk for cancer with long term use.</p><p>Drug Class: <a href="/books/n/livertox/WeightLossAgents/?report=reader">Weight Loss Agents</a></p></div></div><div id="Lorcaserin.PRODUCT_INFORMATION"><h2 id="_Lorcaserin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Lorcaserin – Belviq®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Weight Loss Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lorcaserin" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Lorcaserin.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Lorcaserin_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figLorcaserinTc"><a href="/books/NBK548834/table/Lorcaserin.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figLorcaserinTc" rid-ob="figobLorcaserinTc"><img class="small-thumb" src="/books/NBK548834/table/Lorcaserin.Tc/?report=thumb" src-large="/books/NBK548834/table/Lorcaserin.Tc/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="Lorcaserin.Tc"><a href="/books/NBK548834/table/Lorcaserin.Tc/?report=objectonly" target="object" rid-ob="figobLorcaserinTc">Table</a></h4></div></div></div><div id="Lorcaserin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Lorcaserin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 05 June 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Lorcaserin.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<div><i>(Review of hepatotoxicity published in 1999, well before the availability of lorcaserin).</i></div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.smith.2009.494">Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR., APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT (2C) agonist, reduces body weight in obese men and women. <span><span class="ref-journal">Obesity (Silver Spring). </span>2009;<span class="ref-vol">17</span>:494–503.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19057523" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19057523</span></a>]<div>
|
|
<i>(Randomized controlled trial of 12 weeks of lorcaserin vs placebo in 469 obese subjects; no mention of ALT levels or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.smith.2010.245">Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR., Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:245–56.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20647200" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20647200</span></a>]<div>
|
|
<i>(Randomized controlled trial of 52 weeks of twice daily lorcaserin vs placebo in 3182 obese or overweight patients; serious adverse events included "hepatobiliary disorder" in 0.3% of lorcaserin and 0.3% of placebo recipient; no mention of ALT levels and no clinical details given).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.astrup.2010.288">Astrup A. Drug management of obesity--efficacy versus safety. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:288–90.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20647205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20647205</span></a>]<div>
|
|
<i>(Editorial in response to Smith [2010] reviewing history of weight loss agents used in the United States, many having been withdrawn because of issues of safety of long term use).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.hurren.2011.2029">Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. <span><span class="ref-journal">Am J Health Syst Pharm. </span>2011;<span class="ref-vol">68</span>:2029–37.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22011982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22011982</span></a>]<div>
|
|
<i>(Review of safety and efficacy of lorcaserin for weight loss based upon 3 phase III trials; most common side effects were nausea [8.3%], headache [16.8%], and dizziness [8.5%], but discontinuations for side effects were rare; no mention of ALT levels or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.fidler.2011.3067">Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM., BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:3067–77.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21795446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21795446</span></a>]<div>
|
|
<i>(Randomized controlled trial of two doses of lorcaserin vs placebo for an average of 20 weeks in 4008 obese or overweight patients: "No lorcaserin-associated changes in clinical laboratory parameters... were identified").</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.oneil.2012.1426">O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. <span><span class="ref-journal">Obesity (Silver Spring). </span>2012;<span class="ref-vol">20</span>:1426–36.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22421927" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22421927</span></a>]<div>
|
|
<i>(Randomized controlled trial of lorcaserin vs placebo in 604 overweight or obese patients with diabetes; no mention of ALT levels or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.chan.2013.383">Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. <span><span class="ref-journal">Obes Rev. </span>2013;<span class="ref-vol">14</span>:383–92.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23331711" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23331711</span></a>]<div>
|
|
<i>(Systematic review of results from 5 randomized controlled trials of lorcaserin, only 3 of which used the agent for more than 12 weeks; no mention of hepatotoxicity or ALT elevations).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.nigro.2013.839">Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. <span><span class="ref-journal">Curr Med Res Opin. </span>2013;<span class="ref-vol">29</span>:839–48.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23574263" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23574263</span></a>]<div>
|
|
<i>(Review of the mechanism of action, efficacy and safety of lorcaserin as therapy of obesity; no mention of liver injury or ALT elevations).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.yanovski.2014.74">Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. <span><span class="ref-journal">JAMA. </span>2014;<span class="ref-vol">311</span>:74–86.</span> [<a href="/pmc/articles/PMC3928674/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3928674</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24231879" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24231879</span></a>]<div>
|
|
<i>(Systematic review of the long term efficacy of drug therapies for obesity including lorcaserin, orlistat and phentermine plus topiramate).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF11">Lorcaserin. In obesity: unacceptable risks. <span><span class="ref-journal">Prescrire Int. </span>2014;<span class="ref-vol">23</span>:117–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24926508" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24926508</span></a>]<div>
|
|
<i>(Review of the efficacy and safety of lorcaserin concludes that its weight loss effects are minimal and short lived, and that its costs and risks of adverse events do not warrant its use as therapy of obesity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.halpern.2015.305">Halpern B, Halpern A. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2015;<span class="ref-vol">14</span>:305–15.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25563411" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25563411</span></a>]<div>
|
|
<i>(Review of the safety and efficacy of FDA approved medications for obesity including lorcaserin).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div>
|
|
<i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none of the cases were attributed to a weight loss product such as lorcaserin).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.smith.2017.857">Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, Fujioka K, et al. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. <span><span class="ref-journal">Obesity (Silver Spring). </span>2017;<span class="ref-vol">25</span>:857–65.</span> [<a href="/pmc/articles/PMC5518190/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5518190</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28440045" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28440045</span></a>]<div>
|
|
<i>(Among 235 overweight or obese, non-diabetic adults treated with lorcaserin alone or with phentermine [once or twice daily], weight loss was greater with the combination but so were side effects, but "there was no evidence of hepatic or renal toxicity").</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.bohula.2018.2269">Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, et al. CAMELLIA-TIMI 61 Steering Committee Investigators. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <span><span class="ref-journal">Lancet. </span>2018;<span class="ref-vol">392</span>(10161):2269–79.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30293771" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30293771</span></a>]<div>
|
|
<i>(Among 12,000 overweight or obese adults treated with lorcaserin or placebo for a median of 3.3 years, weight loss was greater with lorcaserin by approximately 2.6 kg; no mention of ALT elevations or other adverse events).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.bohula.2018.1107">Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, et al. CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. <span><span class="ref-journal">N Engl J Med. </span>2018;<span class="ref-vol">379</span>:1107–17.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30145941" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30145941</span></a>]<div>
|
|
<i>(Further analysis of trial of lorcaserin in 12,000 overweight or obese adults focusing upon safety and adverse events mentions adverse events "possible" to include dizziness, fatigue, headache, diarrhea and nausea; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF17">Diet, drugs, devices, and surgery for weight management. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2018;<span class="ref-vol">60</span>(1548):91–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29913463" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29913463</span></a>]<div>
|
|
<i>(Concise review of the medical and surgical therapies for obesity mentions that lorcaserin is a schedule IV controlled substance and only modestly effective for weight loss and that adverse effects include headache, nausea, dizziness, euphoria and impairment of attention and cognition and possibly serotonin syndrome and cardiac valvulopathy; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.tuccinardi.2019.1487">Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, Perakakis N, et al. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial. <span><span class="ref-journal">Diabetes Obes Metab. </span>2019;<span class="ref-vol">21</span>:1487–92.</span> [<a href="/pmc/articles/PMC6504613/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6504613</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30724455" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30724455</span></a>]<div>
|
|
<i>(Among 48 obese adults treated with lorcaserin or placebo for 6 months, weight loss was greater with lorcaserin [-2 vs -0.4 kg] as were decreases in hepatic fat index, while ALT and AST levels were normal and remained normal with therapy).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.saunders.2018.135">Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. <span><span class="ref-journal">Med Clin North Am. </span>2018;<span class="ref-vol">102</span>:135–48.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29156182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29156182</span></a>]<div>
|
|
<i>(Review of the pharmacotherapy of obesity focusing upon the 6 most commonly used medications, discusses the common side effects of lorcaserin including headache, dizziness, fatigue, nausea, dry mouth and constipation, but does not discuss hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.patel.2018.173">Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. <span><span class="ref-journal">Postgrad Med. </span>2018;<span class="ref-vol">130</span>:173–82.</span> [<a href="/pmc/articles/PMC6261426/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6261426</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29388462" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29388462</span></a>]<div>
|
|
<i>(Review of the history of approval and indications, efficacy and long term safety of major currently available weight loss agents including orlistat, phentermine/topiramate, lorcaserin, liraglutide and naltrexone/bupropion; does not discuss hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Lorcaserin.REF21">FDA. Information on Lorcaserin. 2020. Available at: <a href="https://www.fda.gov/media/135189/download" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.fda.gov/media<wbr style="display:inline-block"></wbr>​/135189/download</a>.<div><i>(FDA letter requesting the voluntary withdrawal of lorcaserin because of a secondary analysis of the CAMELLIA-TIMI trial of lorcaserin vs placebo conducted between 2014 and 2018 in 12,000 adults followed for a median of 3.3 years that showed no differences in adverse cardiovascular outcomes, but an imbalance in incidence of cancers arising in 462 patients on lorcaserin [7.7%] vs 427 [7.1%] on placebo with imbalance with several specific forms including pancreatic, colorectal and lung [liver cancer not mentioned]).</i></div></div></li><li><div class="bk_ref" id="Lorcaserin.REF.tak.2020">Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. <span><span class="ref-journal">World J Mens Health. </span>2020 Mar 9;</span> Epub ahead of print. [<a href="/pmc/articles/PMC7994651/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7994651</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32202085" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32202085</span></a>]<div>
|
|
<i>(Review of currently available agents for long term therapy of obesity with specific discussion of mechanism of action, dosing regimen, efficacy and safety, mentions that phentermine/topiramate has the highest rates of weight loss compared to other agents, but also has a high rate of discontinuation because of side effects such as insomnia, paresthesia, dizziness, dry mouth, dysgeusia and constipation and has embryo-fetal toxicity; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK548834_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">June 5, 2020</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Lorcaserin. [Updated 2020 Jun 5].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Lorazepam/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/Lorlatinib/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobLorcaserinTc"><div id="Lorcaserin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548834/table/Lorcaserin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Lorcaserin.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Lorcaserin.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Lorcaserin.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Lorcaserin.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Lorcaserin.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Lorcaserin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lorcaserin</td><td headers="hd_h_Lorcaserin.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135261408" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">616202-92-7</a>
|
|
</td><td headers="hd_h_Lorcaserin.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C11-H14-CI-N</td><td headers="hd_h_Lorcaserin.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/135261408" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=135261408" alt="image 135261408 in the ncbi pubchem database" /></a>
|
|
</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|